Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
Total Equity
Phathom Pharmaceuticals Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Total Equity
-$72.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-124%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$70B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$16.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$92.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$40.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$12.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
39%
|
CAGR 10-Years
-4%
|
See Also
What is Phathom Pharmaceuticals Inc's Total Equity?
Total Equity
-72.8m
USD
Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Total Equity amounts to -72.8m USD.
What is Phathom Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 5Y
-124%
Over the last year, the Total Equity growth was 3%.